The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 04, 2025
Filed:
Jul. 02, 2018
Applicant:
Memorial Sloan Kettering Cancer Center, New York, NY (US);
Inventors:
David A. Scheinberg, New York, NY (US);
Thomas J. Gardner, New York, NY (US);
Derek S. Tan, New York, NY (US);
Jonghan Lee, New York, NY (US);
Ivo Lorenz, New York, NY (US);
Assignee:
Memorial Sloan Kettering Cancer Center, New York, NY (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 9/48 (2006.01); A61K 9/00 (2006.01); A61K 35/17 (2015.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07D 239/94 (2006.01); C07D 501/16 (2006.01); C07D 519/00 (2006.01); C07K 14/52 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
C12N 9/485 (2013.01); A61K 9/0019 (2013.01); A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464412 (2023.05); A61K 39/464453 (2023.05); A61K 39/464454 (2023.05); A61K 39/464489 (2023.05); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07D 239/94 (2013.01); C07D 501/16 (2013.01); C07D 519/00 (2013.01); C07K 14/52 (2013.01); C07K 16/2803 (2013.01); C12N 5/0636 (2013.01); C12Y 304/17011 (2013.01); A61K 38/00 (2013.01); A61K 2239/48 (2023.05); A61K 2239/49 (2023.05); A61K 2239/50 (2023.05); A61K 2239/55 (2023.05); A61K 2239/59 (2023.05); C07K 2317/24 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/35 (2013.01);
Abstract
Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express a tumor antigen-targeted chimeric antigen receptor and a prodrug converting enzyme.